ERBB2 and breast carcinoma: Recently, targeted therapy, such as Trastuzumab and lapatinib to specifically inhibit the activity of receptors HER2/neu and epidermal-derived growth factor receptor (EGFR1), respectively, has already become clinically established as an effective and less toxic strategy for the treatment of breast cancer [1], [2].